TRT and Prostate Cancer Risk: What the Evidence Actually Shows

For most of the 20th century, doctors were taught a simple rule: testosterone "feeds" prostate cancer, so testosterone replacement therapy (TRT) was an absolute contraindication for any man with prostate cancer, past or present, and something to approach cautiously even in healthy men worried about undiagnosed disease. That rule traces back to foundational mid-20th-century research showing prostate cancer is hormone-sensitive — real science that shaped decades of clinical practice. The question is whether it still holds up against the evidence available now, and the honest answer is: it's considerably more nuanced than the old rule suggested, with real caution still warranted in specific situations.

The General Population Question: Does TRT Cause Prostate Cancer?

The largest and most-cited analysis of this question is a 2016 meta-analysis that pooled 20 prospective cohort studies on endogenous (naturally occurring) testosterone levels and prostate cancer risk, plus 26 placebo-controlled TRT trials reporting on PSA and prostate cancer outcomes. For every 5 nmol/L increase in natural testosterone, the summary relative risk of prostate cancer was 0.99 — statistically indistinguishable from no effect at all, with no meaningful variation across the studies [1]. Across the TRT trials, the overall difference in PSA levels after starting treatment was 0.10 ng/mL — a negligible change — and the summary relative risk of prostate cancer as an adverse event from TRT trials was 0.87, again showing no increased risk [1]. The review's own conclusion: "prostate cancer appears to be unrelated to endogenous testosterone levels" and TRT "does not appear to increase PSA levels nor the risk of prostate cancer development" [1].

• •This finding has shifted the leading explanatory model in urology toward what's often called the "saturation model" — the idea that prostate tissue's androgen receptors become fully saturated at relatively low testosterone levels, so that further increases from a low or normal baseline don't meaningfully change how much androgen signaling reaches the prostate [2][4]
• •This is different from saying testosterone has no role in prostate cancer at all — it clearly does, which is exactly why androgen deprivation therapy is a mainstay treatment for advanced prostate cancer — the open question the research above addresses is whether raising testosterone from a low level in a man without aggressive disease meaningfully increases risk, and the evidence says no

What About Men With a Prostate Cancer History?

This is the stricter, more clinically significant question, since it determines whether a prostate cancer survivor with bothersome low-T symptoms can ever be offered treatment. A 2022 review of the literature on TRT in men with a history of prostate cancer concluded that TRT "has a role in patients with localized PCa as it has not been reported to increase rates of recurrence or progression" [2]. A more recent 2026 systematic review focused specifically on oncological safety searched seven databases and, after screening over 2,000 studies down to 9 that met inclusion criteria, found TRT "does not appear to increase the risk of biochemical recurrence, disease progression, or mortality in men with low- to intermediate-risk localized prostate cancer" following radical prostatectomy, radiotherapy, or active surveillance [4].

• •The reassuring findings are specifically for low- to intermediate-risk, localized disease that's already been treated or is under active surveillance — not for every prostate cancer diagnosis
• •Evidence for high-risk or advanced localized disease remains limited, and the same 2026 systematic review explicitly states TRT "continues to be contraindicated in recurrent or metastatic cases outside of clinical trials" [4]
• •A 2024 commentary from radiation and medical oncologists argues the field is at a point where it's "time to take the leap" on offering TRT more readily to appropriately selected prostate cancer survivors, given the quality-of-life and cardiovascular benefits TRT provides balanced against the now-better-understood cancer risk [3]
• •None of this is a blanket green light — it's a case for individualized decisions, made with a urologist or oncologist who knows the specific cancer's risk category and treatment history, not a primary-care-only decision

The Honest Limits of This Evidence

• •Most of the reassuring data in prostate cancer survivors comes from retrospective cohort studies and case series, not large randomized controlled trials specifically designed to test cancer recurrence as the primary endpoint — the 2026 systematic review found only 9 qualifying studies total, and both reviews cited above explicitly call for more research in a randomized setting [2][4]
• •The general-population meta-analysis is large and well-powered for showing TRT doesn't meaningfully raise average PSA or short-term cancer detection — it's less able to rule out very long-term effects over 15-20+ years of continuous use, since most included trials ran for a few years at most [1]
• •"Doesn't appear to increase risk in low-to-intermediate risk localized disease" is a specific, qualified finding — it is not the same claim as "TRT is proven safe for any man with any prostate cancer history," and no reviewed source makes that broader claim
• •Standard practice for any man starting TRT still includes a baseline PSA and digital rectal exam, with periodic PSA monitoring afterward — not because TRT is now considered risk-free, but because routine prostate cancer screening remains appropriate regardless of TRT status

What This Means If You're Considering TRT

• •If you have no prostate cancer history: the evidence doesn't support the old blanket fear that TRT will cause prostate cancer or meaningfully raise your PSA — routine monitoring during treatment is still standard practice, not a special precaution unique to you
• •If you've had low- to intermediate-risk localized prostate cancer that's been treated or is under active surveillance: there's now a real, published evidence base supporting TRT as a reasonable option for some men in this group — this is a conversation to have directly with your urologist or oncologist, not a decision to make alone or avoid out of outdated fear
• •If you have high-risk, recurrent, or metastatic prostate cancer: the current evidence does not support TRT outside of a clinical trial, and this remains an area of real caution, not an open question
• •Whatever your history, a documented PSA trend before and during TRT is the single most useful piece of information for catching anything unexpected early

The Bottom Line

The old blanket rule — testosterone feeds prostate cancer, so TRT is off the table for any man with any prostate cancer connection — doesn't hold up against the modern evidence. For men with no cancer history, large meta-analyses show no meaningful link between testosterone levels and prostate cancer risk. For men with a history of low- to intermediate-risk localized disease, a growing and increasingly specific evidence base supports TRT as a reasonable option in the right circumstances. Real caution still applies to high-risk and metastatic disease, where TRT remains contraindicated outside clinical trials. The right path is an individualized one, made with a specialist who knows your specific history — not a decision driven by a decades-old rule of thumb, in either direction.